ALK and non-small cell lung carcinoma: The expected proportions of ALK positives in each of these increasingly enriched groups, the percentage of the total advanced NSCLC that each group represents, and the estimated numbers of cases found and missed within an initial starting population of 1000 patients with advanced NSCLC are shown in Table 3.